Orphan disease biotech GlycoMimetics revives IPO filing, removes original terms

Comment

Shutterstock photo

GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to sell 4 million shares at $14 to $16 per share but postponed on November 8. The company's updated filing removed the original IPO terms. The Gaithersburg, MD-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol GLYC. GlycoMimetics initially filed confidentially on August 21, 2013. Jefferies and Barclays are the joint bookrunners on the deal. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines IPOs
Referenced Stocks: GLYC


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com